The Hatter Cardiovascular Institute at University College London initiated a series of webinars earlier this year to discuss & debate SGLT2 inhibitors & GLP-1 analogues in the management of Diabetes & Cardio-Renal disease. We are pleased to announce two further webinars continuing on this topic.
**WEBINAR 1 OF 2**
WEBINAR 1: Recognising the importance of informing clinical trainees early in their careers, this is the next in a series of meetings created to address this need, with the programme presenting insight from Consultant level specialists in these areas . Trainees in the specialities of Cardiology, Nephrology and Diabetes are invited to attend.
WEBINAR 2: A further webinar will be held on Friday 24th September at 12pm continuing on from this meeting but will focus on perspectives from SpR's in clinical situations regarding these treatments. NOTE: This will be sent out as a separate event.
All interested trainees simply need to register their interest and join us on FRIDAY the 2nd July, 2021 from 12pm for the webinar which should last approximately 1 to 1.5 hours. THERE IS NO CHARGE TO ATTEND.
Webinar Chairpersons: Professors Derek Yellon, John Cunningham & Stephanie Baldeweg
1. Overview: How do these drugs affect cardiovascular, renal and metabolic medicine?
Prof Niko Marx, Aarchen University Hospital, Aachen, Germany
2. How should the cardiologist manage the renal &/or patient with diabetes?
Prof Malcolm Walker Consultant Cardiologist, UCLH
3. How should the nephrologist manage the cardiovascular and/or patient with diabetes?
Prof David Wheeler, Consultant Nephrologist, Royal Free Hospital, London
4. How should the diabetologist manage the renal &/or cardiovascular patient?
Prof Stephanie Baldeweg, Consultant Diabetologist, UCLH
5. Breakout Discussions by Trainees